Literature DB >> 17728525

A case of deep vein thrombosis and pulmonary thromboembolism after intravenous immunoglobulin therapy.

Yu Ji Lee1, Jae Uk Shin, Jeeyun Lee, Kihyun Kim, Won Seog Kim, Jin Seok Ahn, Chul Won Jung, Won Ki Kang.   

Abstract

Although high-dose intravenous immunoglobulin (IVIG) is generally considered a safe medication for various immune-mediated diseases, thrombotic events have been reported as a complication of the therapy. We report a case who developed thrombotic complications after receiving IVIG. A 56-yr-old woman with idiopathic thrombocytopenic purpura received IVIG at a dose of 400 mg/kg/day for five days. Three days after the administration of IVIG, the patient developed painful edema in the left leg. Lower extremity doppler ultrasound revealed deep vein thrombosis in the left leg. Chest computed tomography (CT) scan demonstrated a filling defect indicating thromboembolism of the right pulmonary artery. After three weeks of enoxaparin therapy, her symptoms and pulmonary embolism on CT improved. This case suggests clinicians should be cautious in the development of thromboembolism by administration of IVIG, especially in patients with thrombophilia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17728525      PMCID: PMC2693835          DOI: 10.3346/jkms.2007.22.4.758

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  18 in total

1.  Intravenous immune globulin use in Canada.

Authors:  Kim Hanna; Melanie Poulin-Costello; Mark Preston; Neil Maresky
Journal:  Can J Clin Pharmacol       Date:  2003

2.  Thrombotic complications after intravenous immunoglobulin therapy in two patients.

Authors:  Geoffrey G Emerson; Christopher N Herndon; Antoine G Sreih
Journal:  Pharmacotherapy       Date:  2002-12       Impact factor: 4.705

3.  Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients.

Authors:  R K Woodruff; A P Grigg; F C Firkin; I L Smith
Journal:  Lancet       Date:  1986-07-26       Impact factor: 79.321

Review 4.  Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature.

Authors:  C Schiavotto; M Ruggeri; F Rodeghiero
Journal:  Haematologica       Date:  1993 Nov-Dec       Impact factor: 9.941

5.  High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.

Authors:  P Imbach; S Barandun; V d'Apuzzo; C Baumgartner; A Hirt; A Morell; E Rossi; M Schöni; M Vest; H P Wagner
Journal:  Lancet       Date:  1981-06-06       Impact factor: 79.321

Review 6.  The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile.

Authors:  Marinos C Dalakas
Journal:  Pharmacol Ther       Date:  2004-06       Impact factor: 12.310

7.  High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events.

Authors:  M C Dalakas
Journal:  Neurology       Date:  1994-02       Impact factor: 9.910

Review 8.  Management of immune thrombocytopenic purpura in adults.

Authors:  Roberto Stasi; Drew Provan
Journal:  Mayo Clin Proc       Date:  2004-04       Impact factor: 7.616

Review 9.  Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature.

Authors:  David Hefer; Mohammed Jaloudi
Journal:  Ann Hematol       Date:  2004-08-10       Impact factor: 3.673

10.  Thromboembolic complications after splenectomy for hematologic diseases.

Authors:  Martin Mohren; Ilka Markmann; Ulrike Dworschak; Astrid Franke; Christian Maas; Sabine Mewes; Günter Weiss; Kathleen Jentsch-Ullrich
Journal:  Am J Hematol       Date:  2004-06       Impact factor: 10.047

View more
  3 in total

Review 1.  Drug-induced thrombosis: an update.

Authors:  Yuval Ramot; Abraham Nyska; Galia Spectre
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

Review 2.  On the dark side of therapies with immunoglobulin concentrates: the adverse events.

Authors:  Peter J Späth; Guido Granata; Fabiola La Marra; Taco W Kuijpers; Isabella Quinti
Journal:  Front Immunol       Date:  2015-02-05       Impact factor: 7.561

3.  Pulmonary Embolism Secondary to Intravenous Immunoglobulin in a Child with Leukemia

Authors:  Işıl Seren Oğuz; Zühre Kaya; Serap Kirkiz; Ülker Koçak
Journal:  Turk J Haematol       Date:  2021-10-07       Impact factor: 1.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.